Context.
A diagnostics company — established, FDA-cleared, with a growing body of clinical evidence — was operating in a contested clinical category where the buying committee was plural (the lab director, the clinician, the procurement lead, the payer) and the analyst posture was weak. The existing positioning was a product feature story; the company needed an equity story.
The operating question: rebuild the positioning from a product feature story to a clinical equity story that defensible to the regulator, the clinician, the payer, and the procurement lead.
Work.
We rebuilt the positioning around the clinical evidence — the trial, the real-world evidence, the meta-analysis — and the operating consequences: a faster time-to-diagnosis, a lower cost of misdiagnosis, a defensible clinical pathway. The positioning was articulated in a 24-page document that became the primer for the analyst relations, the field sales narrative, the customer reference cadence, and the clinical conference presence.
The analyst relations was rebuilt around the lead analyst at the major covering firm, with a 12-month cadence of briefings, data updates, and reference calls. The field sales narrative was rebuilt around the same positioning, with a 4-page sales narrative card and a 24-page clinical evidence binder. The customer reference cadence was rebuilt around the 8 most strategic accounts, with quarterly check-ins and an annual case study.
Decisions.
- Clinical evidence first, brand second. In a regulated category, the clinical evidence is the proof. The brand is the trust. We rebuilt the positioning around the evidence first, the trust second. The order was the discipline.
- One narrative, four audiences. The regulator, the clinician, the payer, and the procurement lead each get a different version of the narrative — but the underlying positioning is the same. The work was the consistency, not the differentiation.
- The analyst is the underwriter. The major analyst is the underwriter of the new positioning. The analyst’s coverage is the public proof; the positioning is the analyst’s coverage. We built the analyst relations around the underwriter, not the secondary firms.
Outcomes.
Over 14 months, the analyst posture moved from a defensive posture to a leading posture in the category. The lead analyst published the first major coverage note on the new positioning within 6 months; the secondary analysts followed within 9 months. The field sales pipeline produced at a steady cadence against a 9-month buying cycle. The customer reference list grew to 12 strategic accounts across 4 sub-categories.
The client and the specific numbers are confidential. The method and the cadence are the public record.